Live Analyst Rating Changes 23828 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yatin Suneja
GUGG

Yatin Suneja

Guggenheim
Wall Street Analyst
★★★☆☆
#1773
on 13Foresight · ranked by our own returns
55%
Success Rate
+6.0%
Average Return
47 of 85 calls profitable · +0.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 55% of Yatin Suneja's ratings turned a profit when each position was held for 1 year — averaging +6.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

150 Buy 4 Hold 0 Sell
Yatin's Stock Coverage 49 ratings · 2026-08-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
IMUX
Immunic
 Aug 11, 2026 BUY Strong Buy
+144.1% avg upside
21 analysts
$70.00
353.02% Upside
 +3.3% ·
ZURA
Zura Bio
 Aug 11, 2026 BUY Strong Buy
+174.1% avg upside
13 analysts
$20.00
247.27% Upside
 +0.0% ·
SION
Sionna Therapeutics, Inc.
 Aug 10, 2026 HOLD Hold
+159.8% avg upside
12 analysts
 — +39.6% ·
AXSM
Axsome Therapeutics
 Aug 10, 2026 BUY Strong Buy
+10.1% avg upside
29 analysts
$275.00
28.10% Upside
 -2.8% ·
ORKA
Oruka Therapeutics
 Aug 10, 2026 BUY Strong Buy
+17.8% avg upside
16 analysts
$200.00
87.31% Upside
 -0.4% ·
ROIV
Roivant Sciences
 Aug 07, 2026 BUY Strong Buy
-1.6% avg upside
17 analysts
$42.00
15.88% Upside
 +0.3% ·
CLYM
Climb Bio
 Aug 07, 2026 BUY Strong Buy
+33.3% avg upside
19 analysts
$35.00
147.00% Upside
 +4.3% ·
CLDX
Celldex
 Aug 06, 2026 BUY Strong Buy
-8.3% avg upside
28 analysts
$100.00
124.99% Upside
 +0.1% ·
OCS
Oculis Holding
 Aug 06, 2026 BUY Strong Buy
+192.2% avg upside
11 analysts
$45.00
247.53% Upside
 +4.0% ·
PRAX
Praxis Precision Medicines
 Aug 06, 2026 BUY Strong Buy
+42.1% avg upside
24 analysts
$800.00
113.54% Upside
 +2.7% ·
AVTX
Avalo Therapeutics
 Aug 06, 2026 BUY Strong Buy
+168.0% avg upside
20 analysts
$48.00
146.91% Upside
 +4.3% ·
XENE
Xenon
 Aug 06, 2026 BUY Strong Buy
-4.0% avg upside
28 analysts
$90.00
38.78% Upside
 -0.5% ·
DNTH
Dianthus Therapeutics
 Aug 05, 2026 BUY Strong Buy
-11.9% avg upside
29 analysts
$200.00
81.78% Upside
 -1.3% ·
SYRE
Spyre Therapeutics
 Aug 04, 2026 BUY Strong Buy
-9.7% avg upside
23 analysts
$130.00
24.98% Upside
 -3.1% ·
ARGX
Argenx Se
 Aug 04, 2026 BUY Strong Buy
-10.3% avg upside
47 analysts
$1185.00
34.78% Upside
 +2.2% ·
REGN
Regeneron
 Aug 03, 2026 BUY Strong Buy
-1.7% avg upside
58 analysts
$1030.00
29.61% Upside
 +5.1% ·
PHAT
Phathom Pharmaceuticals
 Jul 31, 2026 BUY Strong Buy
+195.2% avg upside
14 analysts
$22.00
155.20% Upside
 +3.0% ·
NBIX
Neurocrine
 Jul 31, 2026 BUY Strong Buy
+19.2% avg upside
37 analysts
$222.00
41.10% Upside
 -6.2% ·
BIIB
Biogen
 Jul 21, 2026 BUY Strong Buy
+21.4% avg upside
52 analysts
$280.00
35.48% Upside
 +2.8% ·
DBVT
DBV Technologies SA - American
 Jul 17, 2026 BUY Strong Buy
+69.9% avg upside
15 analysts
$51.00
257.70% Upside
 -4.3% ·
FBRX
Forte Biosciences
 Jul 09, 2026 BUY Buy
-35.4% avg upside
15 analysts
$75.00
2.36% Downside
 +109.3% ·
ABVX
Abivax SA Sponsored ADR
 Jul 01, 2026 BUY Strong Buy
+6.7% avg upside
15 analysts
$175.00
38.17% Upside
 -6.4% ·
EYPT
EyePoint Pharmaceuticals
 Jun 24, 2026 BUY Strong Buy
+152.2% avg upside
20 analysts
$68.00
401.84% Upside
 -6.7% ·
ZBIO
Zenas BioPharma, Inc.
 Jun 05, 2026 BUY Strong Buy
+33.9% avg upside
11 analysts
$55.00
74.25% Upside
 +65.4% ·
IMVT
Immunovant
 May 26, 2026 BUY Strong Buy
-5.1% avg upside
24 analysts
$62.00
48.06% Upside
 +25.7% ·
CABA
Cabaletta Bio
 May 15, 2026 BUY Strong Buy
+393.0% avg upside
16 analysts
$16.00
472.44% Upside
 -15.7% ·
ALMS
Alumis Inc.
 May 15, 2026 BUY Strong Buy
+50.2% avg upside
11 analysts
$34.00
32.83% Upside
 +11.7% ·
SABS
SAB Biotherapeutics
 May 13, 2026 BUY Strong Buy
+182.2% avg upside
14 analysts
$15.00
295.29% Upside
 -4.3% ·
IFRX
InflaRx
 May 08, 2026 BUY Strong Buy
+344.7% avg upside
11 analysts
$14.00
607.17% Upside
 -28.7% ·
NMRA
Neumora Therapeutics, Inc.
 May 07, 2026 BUY Buy
+350.0% avg upside
11 analysts
$14.00
728.43% Upside
 -11.9% ·
STOK
Stoke Therapeutics
 May 07, 2026 BUY Strong Buy
+21.0% avg upside
18 analysts
$60.00
80.09% Upside
 -0.7% ·
ACET
Adicet Bio
 Mar 13, 2026 BUY Strong Buy
+205.9% avg upside
14 analysts
$100.00
1099.03% Upside
 +12.5% ·
ANAB
AnaptysBio
 Mar 04, 2026 BUY Strong Buy
+26.8% avg upside
26 analysts
$140.00
143.20% Upside
 +42.1% ·
MLTX
MoonLake Immunotherapeutics
 Feb 24, 2026 BUY Strong Buy
+70.0% avg upside
20 analysts
$20.00
16.06% Upside
 -5.3% ·
TEVA
Teva Pharmaceutical
 Nov 18, 2025 HOLD Buy
-17.9% avg upside
39 analysts
 — +42.6% ·
LRMR
Larimar Therapeutics
 Sep 29, 2025 BUY Strong Buy
+310.5% avg upside
22 analysts
$26.00
504.57% Upside
 +27.5% ·
ACAD
ACADIA Pharmaceuticals
 Feb 27, 2025 HOLD Strong Buy
+24.3% avg upside
43 analysts
$20.00
32.66% Downside
 +27.0% ·
SRZN
Surrozen
 Jan 03, 2025 BUY Strong Buy
+41.2% avg upside
7 analysts
$45.00
79.55% Upside
 +26.6% ·
QTTB
Q32 Bio
 Dec 11, 2024 HOLD Buy
+288.0% avg upside
24 analysts
 — -46.6% ·
SEELQ
Seelos Therapeutics
 Sep 21, 2023 HOLD Buy
+46385614.3% avg upside
10 analysts
 — · ·
RLMD
Relmada Therapeutics
 Aug 08, 2023 HOLD Buy
+193.5% avg upside
15 analysts
 — -9.4% ·
BTAI
Bioxcel Therapeutics
 Jul 17, 2023 HOLD Buy
+2352.3% avg upside
12 analysts
 — · ·
BLCO
Bausch + Lomb Corporation
 May 31, 2022 BUY Buy
+19.2% avg upside
19 analysts
$24.00
43.19% Upside
 +5.0% ·
XCUR
Exicure
 May 15, 2020 BUY Buy
+7155.2% avg upside
4 analysts
$9.00
564.15% Upside
 · ·
AGIO
Agios Pharma
 Jul 20, 2018 BUY Strong Buy
+84.3% avg upside
29 analysts
$123.00
261.39% Upside
 -48.6% ·
LITS
Lite Strategy
 Jul 13, 2018 BUY Buy
+1082.0% avg upside
13 analysts
$12.00
1186.26% Upside
 · ·
CBIO
Crescent Biopharma
 Dec 12, 2017 BUY Strong Buy
+35.2% avg upside
17 analysts
$32.00
95.41% Upside
 · ·
TGTX
TG Therapeutics
 Oct 18, 2017 BUY Strong Buy
-10.5% avg upside
20 analysts
 — -29.8% ·
OMER
Omeros
 Aug 13, 2014 BUY Buy
+52.7% avg upside
14 analysts
 — -3.4% ·
🔒 44 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yatin Suneja — Frequently Asked Questions
How accurate are Yatin Suneja's stock ratings?
Based on the calls 13Foresight could measure, about 52% of Yatin's ratings were profitable over a one-year hold, with an average return of +6.1% per rating, or +0.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yatin ranked on 13Foresight?
Yatin Suneja is currently ranked #1773 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yatin cover?
Yatin most recently has ratings on IMUX, ZURA, SION, AXSM, ORKA, ROIV, CLYM, CLDX, OCS, PRAX, AVTX, XENE and 37 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.